Cobenfy Kit
Product Images NDC 0003-5200

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Cobenfy (NDC 0003-5200). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by E.r. Squibb & Sons, L.l.c., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Cobenfy 01)

Chemical structure diagram of the active ingredient xanomeline in Cobenfy, showing its molecular configuration with distinct functional groups and ring structures.*

FDA Label Image

Chemical Structure (Cobenfy 02)

Chemical structure diagram depicting the molecular formula of the active ingredient xanomeline, one of the components in the drug product Cobenfy (xanomeline and trospium chloride). The structure includes aromatic rings, a hydroxyl group, and a quaternary ammonium ion with chloride.*

FDA Label Image

Change From Baseline Panss (Cobenfy 03)

A line graph comparing LS mean change from baseline in PANSS total score over 5 weeks between Placebo and Cobenfy treatment groups. The graph shows more reduction in PANSS scores with Cobenfy (dashed line with triangles) than placebo (solid line with circles). The number of patients in each group decreases across the weeks, listed below the x-axis.*

FDA Label Image

50 mg/20 mg Bottle Labels (Cobenfy 04)

Label for Cobenfy capsules containing xanomeline and trospium chloride, with a strength of 50 mg/20 mg per capsule. The label indicates the package contains 60 coated pellet capsules, distributed by Bristol-Myers Squibb Company. It includes storage instructions, dosage recommendations, product barcode, and a QR code.*

FDA Label Image

100 mg/20 mg Bottle Labels (Cobenfy 05)

The image shows a drug label for COBENFY coated pellet capsules containing xanomeline and trospium chloride. The strength is 100 mg xanomeline and 20 mg trospium chloride per capsule. The label states storage instructions, the marketing company Bristol-Myers Squibb, and the package contains 60 capsules. It includes a barcode and notes the drug is Rx only.*

FDA Label Image

125 mg/30 mg Capsule Bottle Label (Cobenfy 06)

Label for Cobenfy capsules containing xanomeline and trospium chloride with a strength of 125 mg/30 mg. The label states the package contains 60 coated pellet capsules for oral use. It includes storage instructions, marketing information from Bristol-Myers Squibb Company, and dosing recommendation to take one capsule twice daily. The NDC and barcode are also visible.*

FDA Label Image

Starter Pack Carton (Cobenfy 07)

Box label for Cobenfy capsules containing xanomeline and trospium chloride. The starter pack includes 56 capsules total: four capsules of 50 mg/20 mg and fifty-two capsules of 100 mg/20 mg strength. Label shows storage instructions, dosage recommendation, and Bristol Myers Squibb as the marketer.*

FDA Label Image

Sample Titration Pack (Image 01)

Label for Cobenfy capsules containing xanomeline and trospium chloride. The label indicates two strengths: 50 mg/20 mg and 100 mg/20 mg per capsule. It is a titration pack with instructions for dosing over 7 days. The pack contains 14 capsules: four capsules of 50 mg/20 mg and ten capsules of 100 mg/20 mg. The label is marked as professional sample, Rx only, from E.R. Squibb & Sons, L.L.C.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.